Nov 14, 2023 / 03:55PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
All right. Very good. It's my pleasure to be hosting this panel with Brett Monia, CEO of Ionis. I'm sure most folks know the Ionis story quite well. But maybe I can just have Brett give a quick 2- to 3-minute intro the scope of the pipeline, what's kind of key and that's upcoming, and then we can get into Q&A. So thank you.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
It sounds good. Pleasure to be here, Paul. Thank you. So Ionis is a genetic medicines company traditionally has been focused on the antisense platform. Today, we're more diversified in our technology. Certainly, [antisense is a key to our] technology with 9 drugs in Phase III development for 11 indications.
But we've also expanded our capabilities into RNAi and even gene editing now. It's been a very exciting year for the pipeline with several positive readouts and preparing for upcoming commercial launches next year
Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers